<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Par7">SNPs prioritized by ML approaches were required to appear in at least two random train-test splits, ensuring more robust associations; they include both known (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) and novel variants (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Gradient boosting machines correctly distinguished the <italic>APOE</italic> haplotypes (Fig.&#160;<xref rid="Fig3" ref-type="fig">3a</xref>, showing distinct clusters). Figure&#160;<xref rid="Fig3" ref-type="fig">3b</xref> further highlights modelling of the <italic>APOE</italic> region across methods, wherein GBMs and NNs correctly identify causal SNPs. Known loci including <italic>CR1, BIN1, IDUA, OTULIN, RASA1, RASGEF1C, CLU, ABCA1, MS4A*, PICALM, ABCA7, APOE, and CASS4</italic> (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) are highlighted by ML models (Fig.&#160;<xref rid="Fig3" ref-type="fig">3c</xref>). In addition, several novel loci were identified with putative biological evidence for association with AD (<italic>ARHGAP25</italic>, <italic>COG7</italic>, <italic>LINC00924/LOC105369212</italic>, <italic>LY6H</italic>, <italic>SOD1</italic> and <italic>ZNF597</italic>) which were replicated in Jansen et al.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Association of an exonic missense variant was also highlighted in <italic>AP4E1</italic>, within 500&#8201;kb of the known <italic>SPPL2A</italic> locus (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Neural networks (NN) detected known loci in <italic>APOE, BIN1, CYP27C1, ABCA1</italic> and <italic>ABCA7</italic> (Fig.&#160;<xref rid="Fig3" ref-type="fig">3c</xref>) and an additional novel locus (<italic>SOD1</italic>), which also replicated in Jansen et al.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). MB-MDR 1&#8201;d identified SNPs in 24 genes, the majority of which map to the <italic>APOE</italic> region, for at least two train-test splits. Of these, 20 were identified by every possible split, indicating highly stable results. MB-MDR 1&#8201;d identified SNP-SNP pairs in the <italic>APOE</italic> region gene consistently through every train-test split. Single train-test splits also find genes outside of Chromosome 19 (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">7</xref>). The majority of candidate novel loci were identified by GBMs, which find multiple loci with evidence for association with AD-related traits such as cognition, pTau, AD age-at-onset and neurofibrillary tangles from previous GWAS (see Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Data&#160;<xref rid="MOESM3" ref-type="media">5</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Association in ML models.</title><p>Uniform Manifold Approximation and Projection (UMAP) of raw (unscaled) SHAP values for GBM hits highlights that <italic>APOE</italic> alleles are identified and drive prediction (<bold>a</bold>). Neural networks and gradient boosting both rank the SNPs required to derive the e2 and e4 allele status for <italic>APOE</italic> as highest, unlike traditional GWAS (<bold>b</bold>). Values for neural networks and GBMs are not based on <italic>p</italic>-values, as described below, while p-values in (<bold>b,</bold><bold>c</bold>) (GWAS) are from a logistic regression in the training split, using a logistic regression and <italic>p</italic>-values from a two-sided Wald test as standard. Manhattan plots are given for top hits only from gradient boosting (mean absolute SHAP values), neural networks (normalised network layer weights) and MB-MDRC 1&#8201;d (&#8722;log10 <italic>p</italic>-values), where hits from different random splits of the models are shown in different colours, and all variants from a single GWAS on the train split are shown in greyscale for comparison (right hand y-axis) (<bold>c</bold>). <italic>p</italic>-values for MB-MDRC 1&#8201;d in (<bold>b</bold>, <bold>c</bold>) are derived from a two-sided permutation-based test as implemented in MDMDR<sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR62">62</xref></sup>. Hits from machine learning models (see Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) are enrichment for known Alzheimer&#8217;s disease processes (<bold>d</bold>).</p></caption><graphic xlink:href="41467_2025_61650_Fig3_HTML" id="d33e5385"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>18 known loci prioritised by machine learning models</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Locus</th><th>Band</th><th>Model</th><th>SNP</th><th>Gene (Known Locus)</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">1q32.2</td><td align="left">A, C</td><td align="left">rs6666604,rs1367068*</td><td align="left"><italic>CR1;CD55</italic></td></tr><tr><td align="left">2</td><td align="left">2q14.3</td><td align="left">A, B, C</td><td align="left">rs79527490,rs3754617*</td><td align="left"><italic>BIN1</italic></td></tr><tr><td align="left">3</td><td align="left">4p16.3</td><td align="left">A, C</td><td align="left">rs4690324,rs4690221*</td><td align="left"><italic>IDUA</italic></td></tr><tr><td align="left">4</td><td align="left">5p15.2</td><td align="left">C</td><td align="left">rs31930,rs11133794</td><td align="left"><italic>OTULIN</italic></td></tr><tr><td align="left">5</td><td align="left">5q14.3</td><td align="left">A, C</td><td align="left">rs4141503</td><td align="left"><italic>RASA1</italic></td></tr><tr><td align="left">6</td><td align="left">5q35.3</td><td align="left">A, C</td><td align="left">rs113706587</td><td align="left"><italic>RASGEF1C</italic></td></tr><tr><td align="left">7</td><td align="left">6p21.1</td><td align="left">C</td><td align="left">rs9381040,rs3747742*</td><td align="left"><italic>TREML2;NFYA</italic></td></tr><tr><td align="left">8</td><td align="left">6p21.32</td><td align="left">A, C</td><td align="left">rs3135392,rs6931277*</td><td align="left"><italic>HLA-DQA2;HLA-DRB5</italic></td></tr><tr><td align="left">9</td><td align="left">8p21.1</td><td align="left">A, C</td><td align="left">rs7831810,rs10866859*</td><td align="left"><italic>EPHX2;CLU;SCARA3 (CLU)</italic></td></tr><tr><td align="left">10</td><td align="left">8p23.1</td><td align="left">C</td><td align="left">rs4731,rs1065712</td><td align="left"><italic>FDFT1</italic></td></tr><tr><td align="left">11</td><td align="left">9q31.1</td><td align="left">B</td><td align="left">rs76996768,rs2777800*</td><td align="left"><italic>ABCA1</italic></td></tr><tr><td align="left">12</td><td align="left">11q12.2</td><td align="left">A, C</td><td align="left">rs983392,rs7232*</td><td align="left"><italic>MS4A6A;MS4A6E</italic></td></tr><tr><td align="left">13</td><td align="left">11q14.2</td><td align="left">A, C</td><td align="left">rs536841,rs471470*</td><td align="left"><italic>PICALM</italic></td></tr><tr><td align="left">14</td><td align="left">14q32.12</td><td align="left">C</td><td align="left">rs10498633,rs12590654</td><td align="left"><italic>RIN3</italic></td></tr><tr><td align="left">15</td><td align="left">15q21.2</td><td align="left">A</td><td align="left">rs2306331</td><td align="left"><italic>AP4E1</italic></td></tr><tr><td align="left">16</td><td align="left">19p13.3</td><td align="left">A, B, C</td><td align="left">rs11672916,rs3795065*</td><td align="left"><italic>ABCA7;CNN2</italic></td></tr><tr><td align="left">17</td><td align="left">19q13.32</td><td align="left">A, B, C, D</td><td align="left">rs7412, rs429358*</td><td align="left"><italic>APOE</italic></td></tr><tr><td align="left">18</td><td align="left">20q13.31</td><td align="left">A, C</td><td align="left">rs6069736,rs6127744</td><td align="left"><italic>RTF2 (CASS4)</italic></td></tr><tr><td align="left">19</td><td align="left">21q21.3</td><td align="left">A</td><td align="left">rs2830500,rs2830520</td><td align="left"><italic>ADAMTS1</italic></td></tr></tbody></table><table-wrap-foot><p>Loci are defined as known if genome-wide significant in major AD GWAS (Supplementary Data&#160;<xref rid="MOESM3" ref-type="media">1</xref>) and containing at least one SNP in the top variant list from an ML model (A: GBM, B: NN, C: MB-MDRC 1&#8201;d, D: MB-MDRC 2&#8201;d). Chromosomal bands use build GRCh38p.14 from Ensembl release 111 in BiomaRt. *SNP list curtailed at two rsids: see Supplementary Data&#160;<xref rid="MOESM3" ref-type="media">5</xref> for full list.</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>34 putative novel loci prioritised from machine learning models</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Locus</th><th>Band</th><th>Model</th><th>SNP</th><th>Gene</th><th>Replication <italic>p</italic>-value</th><th>Summarised GWAS Catalogue Traits</th></tr></thead><tbody><tr><td align="left"><bold><italic>1</italic></bold></td><td align="left"><bold><italic>2p13.3</italic></bold></td><td align="left"><bold><italic>A</italic></bold></td><td align="left"><bold><italic>rs80275456</italic></bold></td><td align="left"><bold><italic>ARHGAP25</italic></bold></td><td align="left"><bold><italic>0.0116&#8224;</italic></bold></td><td align="left"><bold><italic>Blood count, Psychiatric disorders, Lipid metabolism</italic></bold></td></tr><tr><td align="left">2</td><td align="left">3p21.1</td><td align="left">A</td><td align="left">rs3774423</td><td align="left"><italic>CACNA1D</italic></td><td align="left">0.7828</td><td align="left">CVD, Sleep, Cognition, Adiposity, Smoking</td></tr><tr><td align="left">3</td><td align="left">3p24.1</td><td align="left">B</td><td align="left">rs2371108,rs9828781</td><td align="left"><italic>EOMES</italic></td><td align="left">0.6256</td><td align="left">Inflammation, Arthritis, Blood count</td></tr><tr><td align="left">4</td><td align="left">3p25.1</td><td align="left">A</td><td align="left">rs7636739</td><td align="left"><italic>SH3BP5</italic></td><td align="left">0.781</td><td align="left">Smoking, Alcohol</td></tr><tr><td align="left">5</td><td align="left">3p25.2</td><td align="left">A</td><td align="left">rs7645264</td><td align="left"><italic>RPL32</italic></td><td align="left">0.9424</td><td align="left">Adiposity</td></tr><tr><td align="left">6</td><td align="left">4q21.22</td><td align="left">B</td><td align="left">rs17005633</td><td align="left"><italic>HNRNPDL</italic></td><td align="left">0.4745</td><td align="left"/></tr><tr><td align="left">7</td><td align="left">4q27</td><td align="left">A</td><td align="left">rs75623120</td><td align="left"><italic>TRPC3</italic></td><td align="left">0.2129</td><td align="left">Inflammation</td></tr><tr><td align="left">8</td><td align="left">4q34.3</td><td align="left">A</td><td align="left">rs1363592,rs2546251</td><td align="left"><italic>LINC00290</italic></td><td align="left">0.4379</td><td align="left">AD in APOE-e4, CSF AB1-42 levels, CAA x APOE-e4, Psychiatric disorders</td></tr><tr><td align="left">9</td><td align="left">6p21.33</td><td align="left">A</td><td align="left">rs12210887</td><td align="left"><italic>LSM2</italic></td><td align="left">0.933</td><td align="left">Psychiatric disorders, Inflammation, Infection</td></tr><tr><td align="left">10</td><td align="left">6p22.2</td><td align="left">A</td><td align="left">rs9393777</td><td align="left"><italic>BTN3A1</italic></td><td align="left">0.6977</td><td align="left">Diabetes, Psychiatric disorders, Cognition, Adiposity</td></tr><tr><td align="left">11</td><td align="left">7p15.3</td><td align="left">A</td><td align="left">rs11770728</td><td align="left"><italic>CCDC126</italic></td><td align="left">0.0832</td><td align="left">Liver, Cardiovascular function</td></tr><tr><td align="left">12</td><td align="left">7p21.2</td><td align="left">A</td><td align="left">rs10486769,rs16878585</td><td align="left"><italic>MEOX2</italic></td><td align="left">0.0564</td><td align="left">CVD, Lipid metabolism, Brain volume,Adiposity</td></tr><tr><td align="left">13</td><td align="left">8p12</td><td align="left">A</td><td align="left">rs76461905,rs11780927</td><td align="left"><italic>RNF122;DUSP26</italic></td><td align="left">0.4174</td><td align="left">Sleep, BMI, Pulse pressure</td></tr><tr><td align="left">14</td><td align="left">8p23.2</td><td align="left">A</td><td align="left">rs11136920</td><td align="left"><italic>CSMD1;LOC100287015</italic></td><td align="left">0.4383</td><td align="left">AD, CVD, Inflammation, Sleep, Diabetes, Psychiatric disorders, Smoking, Lipid metabolism</td></tr><tr><td align="left">15</td><td align="left">8p23.3</td><td align="left">A</td><td align="left">rs1550948,rs73175035</td><td align="left"><italic>FBXO25</italic></td><td align="left">0.0617</td><td align="left">Inflammation, Alcohol, Moyamoya disease</td></tr><tr><td align="left">16</td><td align="left">8q21.13</td><td align="left">A</td><td align="left">rs11778492</td><td align="left"><italic>ZC2HC1A</italic></td><td align="left">0.2123</td><td align="left">Depression, Inflammation, Weight</td></tr><tr><td align="left">17</td><td align="left">8q21.13</td><td align="left">A</td><td align="left">rs11987678</td><td align="left"><italic>TPD52</italic></td><td align="left">0.6003</td><td align="left">Inflammation, Diabetes, Sleep</td></tr><tr><td align="left"><bold><italic>18</italic></bold></td><td align="left"><bold><italic>8q24.3</italic></bold></td><td align="left"><bold><italic>A</italic></bold></td><td align="left"><bold><italic>rs7013750</italic></bold></td><td align="left"><bold><italic>LY6H</italic></bold></td><td align="left"><bold><italic>0.0449&#8224;</italic></bold></td><td align="left"><bold><italic>Smoking, Diabetes, Cognition</italic></bold></td></tr><tr><td align="left">19</td><td align="left">13q14.13</td><td align="left">A</td><td align="left">rs9567575</td><td align="left"><italic>SIAH3</italic></td><td align="left">0.8082</td><td align="left">NFTs, Clusterin levels, Diabetes, Cortical surface area, Cardiovascular function</td></tr><tr><td align="left">20</td><td align="left">13q33.1</td><td align="left">A</td><td align="left">rs1333277</td><td align="left"><italic>DAOA-AS1;LINC01309</italic></td><td align="left">0.0992</td><td align="left">Smoking, Diabetes, Cognition, CSF TREM-2, PHF-tau, Adiposity</td></tr><tr><td align="left">21</td><td align="left">14q11.2</td><td align="left">A</td><td align="left">rs1107390</td><td align="left"><italic>DAD1;ABHD4</italic></td><td align="left">0.991</td><td align="left">Inflammation, liver function</td></tr><tr><td align="left">22</td><td align="left">14q32.33</td><td align="left">A</td><td align="left">rs7143644</td><td align="left"><italic>C14orf180;TMEM179;INF2</italic></td><td align="left"/><td align="left">Inflammation, Psychiatric disorders</td></tr><tr><td align="left">23</td><td align="left">15q21.1</td><td align="left">A</td><td align="left">rs498976</td><td align="left"><italic>SEMA6D</italic></td><td align="left">0.9661</td><td align="left">Cognition, Psychiatric disorders, Sleep, Longevity, Smoking, Anthropometric traits</td></tr><tr><td align="left"><bold><italic>24</italic></bold></td><td align="left"><bold><italic>15q26.2</italic></bold></td><td align="left"><bold><italic>A</italic></bold></td><td align="left"><bold><italic>rs117354036,rs4247092</italic></bold></td><td align="left"><bold><italic>LINC00924;LOC105369212</italic></bold></td><td align="left"><bold><italic>0.0345&#8224;</italic></bold></td><td align="left"><bold><italic>Cognition in MCI, Inflammation, Smoking, CVD</italic></bold></td></tr><tr><td align="left">25</td><td align="left">15q26.2</td><td align="left">A</td><td align="left">rs12911308</td><td align="left"><italic>MCTP2</italic></td><td align="left">0.0788</td><td align="left">CSF pTau in AD, CVD, Inflammation, Diabetes, Psychiatric disorders</td></tr><tr><td align="left">26</td><td align="left">15q26.3</td><td align="left">A</td><td align="left">rs12901450,rs8035839</td><td align="left"><italic>TARS3</italic></td><td align="left">0.7071</td><td align="left"/></tr><tr><td align="left"><bold><italic>27</italic></bold></td><td align="left"><bold><italic>16p12.2</italic></bold></td><td align="left"><bold><italic>A</italic></bold></td><td align="left"><bold><italic>rs250583</italic></bold></td><td align="left"><bold><italic>COG7</italic></bold></td><td align="left"><bold><italic>0.001&#8224;</italic></bold></td><td align="left"><bold><italic>Cholesterol x fenofibrate</italic></bold></td></tr><tr><td align="left"><bold><italic>28</italic></bold></td><td align="left"><bold><italic>16p13.3</italic></bold></td><td align="left"><bold><italic>A</italic></bold></td><td align="left"><bold><italic>rs4786422</italic></bold></td><td align="left"><bold><italic>ZNF597</italic></bold></td><td align="left"><bold><italic>0.0227&#8224;</italic></bold></td><td align="left"/></tr><tr><td align="left">29</td><td align="left">17p13.1</td><td align="left">C</td><td align="left">rs11078722</td><td align="left"><italic>KCNAB3</italic></td><td align="left">0.2143</td><td align="left">Smoking, Blood pressure</td></tr><tr><td align="left">30</td><td align="left">18q12.2</td><td align="left">A</td><td align="left">rs17561693,rs1941955</td><td align="left"><italic>MIR4318;MIR924HG;CELF4</italic></td><td align="left">0.349</td><td align="left">Smoking, Obesity, Diabetes, Psychiatric disorders, Sleep</td></tr><tr><td align="left">31</td><td align="left">18q21.33</td><td align="left">A</td><td align="left">rs694419,rs17729530</td><td align="left"><italic>ZCCHC2</italic></td><td align="left">0.2432</td><td align="left">PHF-Tau, Sleep, Psychiatric disorders, Inflammation, Cognition, Adiposity</td></tr><tr><td align="left">32</td><td align="left">20q11.22</td><td align="left">A</td><td align="left">rs910873</td><td align="left"><italic>ASIP</italic></td><td align="left">0.942</td><td align="left">AD AAO, Skin cancer, Smoking</td></tr><tr><td align="left"><bold><italic>33</italic></bold></td><td align="left"><bold><italic>21q22.11</italic></bold></td><td align="left"><bold><italic>B</italic></bold></td><td align="left"><bold><italic>rs4998557,rs4816407*</italic></bold></td><td align="left"><bold><italic>SOD1</italic></bold></td><td align="left"><bold><italic>0.0147&#8224;</italic></bold></td><td align="left"><bold><italic>ALS, Globulin-levels</italic></bold></td></tr></tbody></table><table-wrap-foot><p>Top predictors from machine learning models within 500&#8201;kb of each other were merged using bedtools v2.27.1, or if functionally or positionally annotated with the same gene. We prioritise the 34 loci which have support from more than one split in a machine learning model (A: GBM, B: NN, C: MB-MDRC 1&#8201;d, D: MB-MDRC 2&#8201;d) or replication in an external dataset (Jansen et al., 2019<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>), defined as at least one SNP from the listed rsIDs in that row of the table which is present at <italic>p</italic>&#8201;&#8804;&#8201;0.05 in publicly available summary statistics. Chromosomal bands were extracted for GRCh38p.14 from Ensembl release 111 using BiomaRt; gene annotation methodology is described in the methods section. The direction of effect is not included here as for ML approaches no single direction is obtained: different subgroups may have varying associations with the outcome for a given SNP. Consequently, direction of effect is not as informative as in standard GWAS replication studies. Traits related to AD and dementia which were annotated from the GWAS catalogue and summarised; a full list of traits from past GWAS and corresponding PubMed IDs is given in Supplementary Data&#160;<xref rid="MOESM3" ref-type="media">5</xref>. *SNP list curtailed at two rsids: see Supplementary Data&#160;<xref rid="MOESM3" ref-type="media">5</xref> for full list. &#8224;Nominally significant in the replication. Putative novel loci (emphasised) are discussed in the manuscript.</p></table-wrap-foot></table-wrap></p>